AZNAstraZenecaSigning up patients
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Advanced Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 24 (planned)
- Started
- May 6, 2026
- Main results expected
- Dec 28, 2027
- Fully finished
- Dec 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with adverse events (AEs) and serious AEs
Measured over: Up to Post-Treatment Follow up (Day 30 Post Dose)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07427394 · record last updated 2026-09-29 · checked 2026-11-09 15:47 UTC